Get clear answers before making a decision
If you are considering regenerative treatment, it helps to know what to ask before you commit to a procedure or a trip. A consultation should leave you with a clear picture of what is being proposed, why it might fit your situation and what is still uncertain.
These questions are a starting point for that conversation. Bring the ones that matter to you, and ask for answers you can take away and discuss with your usual clinician.
1. Who is making the medical recommendation?
Ask for the name of the clinician responsible for assessing you and providing treatment, where they are licensed, and their experience with your condition. Clarify what the coordinator does and which decisions belong to the clinical team. Ask how your current care and other treatment options will be considered. [1]
2. What exactly would I receive?
Ask for the product name, source, preparation and proposed route in writing. For cell-based treatment, ask whether the cells come from you or a donor and how they are processed. Broad labels such as stem cells do not identify a particular preparation. [1]
Ask who manufactures it and what documentation applies to the batch you would receive. For example, ask the clinical team to explain its identity, contamination testing, handling and storage. EMA identifies contamination, inconsistent composition and improper storage as risks where advanced therapies lack appropriate oversight. A laboratory report needs interpretation alongside clinical evidence and regulatory status. [5]
3. Which findings apply to someone like me?
Ask for the original studies. Look at who took part, how many people were studied, what they received and what the comparison group received. Randomized trials use chance to assign treatment and reduce bias; an improvement after treatment alone does not tell you how much was caused by it. [2]
People
Did participants have your condition and a similar level of illness?
Product
Was the same preparation and route studied?
Outcome
Was the result a change in daily function, symptoms or a laboratory measurement?
Time
How long did follow-up last, and how many participants completed it?
Ask about negative or inconclusive findings too. Our guide to reading a study works through actual trial examples. You can also search the research library for the original papers.
4. What are the risks and the gaps in knowledge?
Ask which problems have been reported with this product and procedure, how often they occurred and how long people were followed. Ask separately about uncertainty: which risks have not been adequately studied? FDA has received serious adverse-event reports involving unapproved regenerative products, including infections. Those reports establish that harm can occur; they do not provide a personal risk estimate for every product. [3]
Have the treating clinician review your medical history, allergies, medicines and supplements. Ask what would make them advise against proceeding, and what monitoring would be needed.
5. What permits this treatment in the country where it happens?
Ask the clinic to identify the precise regulatory route, responsible authority and supporting documents. Approval for one product or use does not answer the question for every treatment offered under a similar name.
- United States: FDA cautions that registration with the agency or a ClinicalTrials.gov listing can be used misleadingly. Ask what authorization applies to the proposed product and use. [3]
- European Union: EMA advises patients to check advanced-therapy approval with the relevant national authority. Ask which authorization covers the actual treatment location and product. [5]
- United Kingdom: MHRA distinguishes marketing authorization from routes for unlicensed advanced therapies, including hospital exemption and specials. Those routes have specific requirements; they are not interchangeable with marketing approval. [6]
- Canada: Health Canada directs patients to its Drug Product Database and Clinical Trials Database to check authorized products and trials. Check the current record for the exact proposal. [7]
If a compounded medicine is proposed, ask a separate question about lawful compounding of that particular substance. FDA states that compounded drugs are not FDA-approved, while recognizing their role in meeting certain medical needs. A prescription or facility credential does not turn a compounded preparation into an approved drug. [4]
If the proposal is a clinical trial, ask for the registry number, named investigator, site and oversight documents. NIH explains that a study listing is not government evaluation or endorsement. Ask whether the record describes planned research or includes completed results. [8]
6. Who looks after me afterward?
Agree on follow-up before travelling: the clinician responsible, planned appointments, how results will be shared and who to contact if something goes wrong. Ask how local care would be arranged if you return home with a complication. CDC recommends planning follow-up in advance and obtaining your treatment records before leaving the treating facility. [9]
Include the practical details: language support, a written discharge plan and whether your insurer covers complications from planned treatment abroad. Do not assume ordinary travel insurance includes that cover. [9]
7. What am I agreeing to, and what could it cost?
Request the consent information before the treatment day. It should give you a meaningful explanation of the proposed intervention and its risks, with time to ask questions. ISSCR's consent standard addresses the information patients need before stem-cell interventions outside formal trials. [10]
Ask for an itemized written estimate covering assessment, treatment, tests and follow-up. Check what is excluded, when payments become non-refundable and what happens if the clinician decides you should not proceed. Plan for possible extra travel or medical costs rather than assuming the initial quote covers everything. [9]
8. Can I take this away and get another opinion?
Ask for the proposal, source papers and consent documents to review with a clinician familiar with your condition. A clear discussion should leave room for questions and alternatives. ISSCR recommends independent advice and time to consider the decision without financial pressure. [1]
What to take from this
- Write down the actual proposal, the evidence offered and the questions still unanswered.
- Keep product quality, clinical evidence and legal access as separate checks.
- Know who is responsible for your care during treatment and after you return home.
Questions people ask
Does a clinical trial listing mean a treatment is approved?
No. A registry entry describes a study; it is not product approval or an endorsement. Check the study sponsor, recruiting site, regulatory and ethics oversight, and whether published results exist. NIH explains that listing a study does not mean the US government has evaluated it.
Does a compounded prescription mean the medicine is FDA-approved?
No. FDA states that compounded drugs are not FDA-approved. Lawful compounding can meet a medical need, but the exact substance and applicable requirements still need checking. A prescription or a facility credential does not settle those questions.
Can I take time to get another opinion?
Yes. Ask for the written proposal, evidence and consent information so you can discuss them with a clinician who understands your condition. You should have room to consider alternatives and decide whether to proceed.
Sources and further reading
Sources checked October 20, 2026. These are regulator, public-health and professional guidance sources, not a clinical trial of a treatment. Country examples explain what to verify; they do not confirm the authorization or suitability of any individual provider or product.
This article is for education and consultation preparation. It is not medical or legal advice, a treatment recommendation or verification of a provider's authorization. Check the applicable regulator's current requirements. Any treatment decision should be made with a qualified physician. Individual results vary.